EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Calprotectin as new potential clinical marker for multiple myeloma

Parisa Khosravi iD, Saeid Abroun, Saeid Kaviani, Saman Masoudifar, Homayoun Sarough Farahani

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0282841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Parisa Khosravi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tarbiat Modares University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in μg/g of feces. Values ​​above 50 μg/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexMultiple MyelomaHumansBiomarkersCase-Control StudiesEnzyme-Linked Immunosorbent AssayFecesInflammationIran

Substanzen

BiomarkersLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Arak university of Medical Science, Arak, Iran.

ORCID-Profile: Parisa Khosravi

Förderung

  • Tarbiat Modares University

Zitieren

APA

Khosravi, P., Abroun, S., Kaviani, S., Masoudifar, S., & Farahani, H. S. (2023). Calprotectin as new potential clinical marker for multiple myeloma. PLOS ONE. https://doi.org/10.1371/journal.pone.0282841

Vancouver

Khosravi P, Abroun S, Kaviani S, Masoudifar S, Farahani HS. Calprotectin as new potential clinical marker for multiple myeloma. PLOS ONE. 2023. doi:10.1371/journal.pone.0282841

BibTeX
@article{Khosravi2023,
  author = {Khosravi, Parisa and Abroun, Saeid and Kaviani, Saeid and Masoudifar, Saman and Farahani, Homayoun Sarough},
  title = {Calprotectin as new potential clinical marker for multiple myeloma},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0282841}
}
Kostenlos starten →